With Covid-19 Halting Clinical Trials, Wearables Could be Key — But Data ‘Wild West’ Gets in the Way Date Published: Aug 11, 2020 Article Before the Covid-19 pandemic, leveraging digital technologies in medical product development seemed impossible with the industry’s patient recruitment, timeline, and success rate struggles. However the global lockdown forced researchers to reconsider, forever changing how clinical trials are conducted. For the first time ever, pharmaceutical and technology companies collaborated to develop common study standards and protocols. But this is just the start. Find out why this collaboration needs to continue to improve clinical trials beyond the pandemic. Read More Share: LinkedIn0Tweet0 Recommended Resources Article A New Approach to Diagnosing and Treating Major Depressive Disorder Can a blood test predict treatment response to antidepressants? Recent research conducted by Signant’s scientific director, Steven Targum, M.D., along... Download Article Visual Analog Scale: Paper Versus Electronic Administration Comparison Increasing digitalization of clinical outcome assessments prompts questions about equivalence between data captured from paper and electronic instrument versions. Signant’s... Download Now Article How To Run a Successful, Decentralized Oncology Trial Oncology research continues to undergo rapid transformation, driven by a number of factors including: Increased interest in understanding the patient... Download Now